• Home
  • News and Events
  • News
  • Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

14Dec

Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

READ ARTICLE

Share this post